DOCM.SW DocMorris AG (SIX) 20 Mar 2026 earnings recap: guidance and next moves

DOCM.SW stock closed at CHF 4.01 on the SIX in Switzerland as markets shut on 20 Mar 2026. DocMorris AG reported results and reiterated a 2026 target to reach EBITDA break-even. Investors will watch guidance, cash metrics and margins after the print. This earnings spotlight explains the numbers, market reaction, valuation and near-term forecast from Meyka AI

DOCM.SW stock: headline results and guidance

DocMorris AG presented an earnings update tied to a path to EBITDA break-even in 2026. The company confirmed the earnings announcement on 20 Mar 2026 and issued new revenue direction. Market response left the share price at CHF 4.01, trading between CHF 4.01 and CHF 4.48 intraday. Volume was 452005 shares, above the 50-day average of 286780.

DOCM.SW stock: profit and cash metrics

DocMorris shows negative EPS of -4.58 and a trailing PE of -0.89, reflecting recent losses. Cash per share stands at 7.89, and the current ratio is 3.25, supporting near-term liquidity. Free cash flow per share is negative at -2.48, so operational cash recovery is the key to meeting the 2026 EBITDA goal.

DOCM.SW stock: valuation and sector context

Valuation ratios show low market pricing: price-to-sales is 0.18 and price-to-book is 0.24. By contrast the Swiss healthcare sector average PE is 26.92, and sector YTD is -6.79%. The low multiples reflect persistent losses and restructuring costs, while book value per share of 16.47 suggests balance sheet support.

DOCM.SW stock: technicals and trading reaction

Technicals show oversold conditions with RSI 25.69 and MACD -0.37. Momentum indicators flagged sharp declines year-on-year of -77.39%. Short-term support sits near the day low CHF 4.01 and the 200-day average is CHF 6.12. Watch volume and a break above CHF 5.42 for a shift in trend.

DOCM.SW stock: Meyka grade and analyst framework

Meyka AI rates DOCM.SW with a score out of 100: Meyka AI rates DOCM.SW with a score of 63.64 (Grade B) and suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights balanced risk: solid liquidity but weak profitability.

DOCM.SW stock: forecast, scenarios and price targets

Meyka AI’s forecast model projects monthly CHF 2.09 and quarterly CHF 5.56 outcomes. Versus the current price CHF 4.01, that implies a model-based downside of -47.88% for the monthly path and an upside of 38.65% for the quarterly path. Scenario price targets: conservative CHF 3.00, base CHF 4.50, and upside CHF 7.50. Forecasts are model-based projections and not guarantees.

Final Thoughts

DOCM.SW stock closed at CHF 4.01 after DocMorris AG published results and reiterated a 2026 EBITDA break-even target. The company combines a sound cash buffer of CHF 7.89 per share and a high current ratio of 3.25, but trailing EPS of -4.58 and negative free cash flow remain material risks. Valuation metrics are low, with P/S 0.18 and P/B 0.24, which signals market skepticism. Technically, RSI 25.69 suggests oversold conditions, while volume of 452005 shares shows heightened attention. Meyka AI rates DOCM.SW 63.64 (Grade B, HOLD) and projects a monthly model path to CHF 2.09 and a quarterly path to CHF 5.56, implying scenario downside of -47.88% or upside of 38.65% versus today’s price. Investors should track margin improvement, cash conversion, and management’s execution on the EBITDA target. For more detail, see the company note and market coverage on Meyka AI and the full news bulletin source and internal data at Meyka DOCM.SW page. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.